|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Health Conditions > Osteoporosis > Evista
(raloxifene)
Evista® (raloxifene)
Where to Purchase:
Related Topics:
News & Research:
-
Drugs Can Cut Breast Cancer Risk for Some, Task Force Finds - WebMD,
4/15/13 - "One of the report's key findings was that
studies of tamoxifen reported a decrease in breast cancer incidence from
23.5 per 1,000 women in the placebo group to 16.5 per 1,000 among women
taking tamoxifen over a five-year period ... Tamoxifen is more effective at
reducing breast cancer risk, but it has more side effects ... there were
five fewer cancers per 1,000 women taking tamoxifen when compared with
raloxifene ... For tamoxifen, 8.6 per 1,000 women experienced a blood clot
compared with 4.6 per 1,000 in the "control" group ... The rates of
endometrial cancer, or cancer of the uterus, and cataracts were also higher
for women taking tamoxifen, but not for those taking raloxifene"
-
Medications Effective In Reducing Risks For Breast Cancer Can Also Cause
Serious Side Effects - Science Daily, 9/18/09 -
"The most common side effects for tamoxifen are flushing and other vasomotor
symptoms (e.g., night sweats, hot flashes), vaginal discharge and other
vaginal symptoms such as itching or dryness; for raloxifene, side effects
include vasomotor symptoms and leg cramps; and for tibolone, side effects
include vaginal bleeding ... Tamoxifen increases risks of endometrial
cancer, hysterectomies and cataracts compared with the other drugs.
Tamoxifen and raloxifene increase risk of blood clots, although tamoxifen's
risk is greater. Tibolone carries an increased risk of stroke"
-
Agent Reduces Breast Cancer Risk in Two Groups of Women - Physician's
Weekly Article, 12/17/07 - "raloxifene hydrochloride
reduced the risk of invasive breast cancer by 44% to 71% by blocking
estrogen receptors in the breast"
-
FDA Panel OKs Evista for Breast Cancer - WebMD, 7/24/07
-
Raloxifene Reduces Breast Cancer Risk in Postmenopausal Women at All Risk
Levels - Doctor's Guide, 9/13/06 -
"use of raloxifene was associated
with a 58 percent reduction in breast cancer risk in women without a family
history of the disease, and an 89 percent reduction in risk for women with a
family history of breast cancer" - See raloxifene at OffshoreRx.com.
-
Evista: Help for Breast Cancer, Heart? - WebMD, 7/12/06
-
Major Study Evaluates Benefits and Risks of Tamoxifen and Raloxifene for
Reducing the Risk of Breast Cancer - Doctor's Guide, 7/4/06
-
Benefits and Risks of Tamoxifen, Raloxifene for Reducing Risk of Breast
Cancer - Doctor's Guide, 6/6/06
-
Osteoporosis Drug Raloxifene Shown to Be as Effective as Tamoxifen in
Preventing Invasive Breast Cancer - Doctor's Guide, 4/17/06
-
Lilly Announces Preliminary Coronary and Breast Cancer Results from
Raloxifene Use for The Heart (RUTH) Study - Doctor's Guide, 4/12/06
-
Drug May Slow Prostate Cancer - WebMD, 3/29/06
-
Raloxifene, Drug Used For Osteoporosis, Shown To Potentially Benefit
Prostate Cancer Patients - Science Daily, 3/24/06
-
Low Endogenous Estradiol, Raloxifene (Evista), Linked to Decreased Stroke
Risk in Postmenopausal Women - Doctor's Guide, 2/21/06
-
New Data Provide In-Depth, Safety Information on Long-Term use of Evista(R)
- Doctor's Guide, 9/28/05
-
Raloxifene May Help Prevent Endometrial Cancer - Doctor's Guide, 5/18/05
-
Evista May Help Prevent Endometrial Cancer - WebMD, 5/16/05
-
Long-Term Data Show Raloxifene May Protect Against Invasive Breast Cancer
- Doctor's Guide, 5/11/05
-
Osteoporosis Drug May Help Preserve Memory - WebMD, 4/8/05
-
Less Cognitive Impairment Seen in Women Taking Drug for Osteoporosis -
Doctor's Guide, 4/7/05 - "The drug,
raloxifene, modulates the activity of the hormone estrogen ... the 120 mg
dose conferred a 33% lower risk of developing mild cognitive impairment when
compared with the 60 mg dose and with placebo. The 60 mg dose offered no
apparent prevention of cognitive impairment. While researchers also observed
a reduced risk of developing Alzheimer's disease, that reduction was of
borderline statistical significance"
-
Study Finds Continued Reduction In Breast Cancer Incidence Associated With Longer Use Of Raloxifene - Science Daily, 12/14/04
-
Osteo Drug May Prevent Breast Cancer - HealthDay, 11/30/04 -
"That trial lasted four years and found that the incidence of breast cancer was 72 percent lower
in women taking raloxifene than it was in women taking a placebo"
-
Raloxifene Protective against Breast Cancer Regardless of HRT Use - Doctor's Guide, 11/4/04
-
Osteoporosis Drug May Prevent Breast Cancer - WebMD, 11/2/04
-
Raloxifene Appears to be Associated With Doubled Risk OF Venous Thromboembolic Event Over Long Term - Doctor's Guide, 10/11/04
-
Long-Term Raloxifene Associated With Halving of Breast-Cancer Risk in Post-menopausal Women - Doctor's Guide, 6/8/04
- Osteoporosis Drug May Prevent Breast Cancer - WebMD, 6/7/04
-
Weekly Fosamax (Alendronate) Shows Benefits Over Daily Evista (Raloxifene) for Bone density and Bone Turnover Markers at 6 Months - Doctor's Guide, 5/21/04
-
Study Favors Premarin for Osteoporosis - HealthDay, 4/26/04 -
"three-year study ... Bone density declined by 2 percent in the placebo group, remained stable in the two raloxifene
groups, and increased by 4.6 percent in the CEE group"
-
Alendronate May Offer Better Improvements in Bone Mineral Density and Bone Turnover Than Raloxifene - Doctor's Guide, 4/13/04
-
Raloxifene Confers Multiple Lipid Benefits in Postmenopausal Osteoporotic Women - Doctor's Guide, 3/8/04
-
Raloxifene For Osteoporosis Significantly Decreases Biochemical Markers Of Bone Turnover Related To Fracture Risk - Doctor's Guide, 2/26/04
-
Long-term Raloxifene Treatment May Reduce Insulin Sensitivity - Doctor's Guide, 2/16/04
-
'Designer' Estrogen Shows Promise for Menopausal Problems - HealthDay, 2/2/04
- Evista Stops Growth of Uterine Fibroids - WebMD, 1/14/04
-
Alendronate Superior to Raloxifene in Increasing Bone Mineral Density - Doctor's Guide, 10/7/03
-
Significant Increases in Bone Mineral Density With Alendronate Over Raloxifene in Head-To-Head Study - Doctor's Guide, 10/6/03 -
"In the first head-to-study comparing a weekly dosage of alendronate with a daily dosage of raloxifene for postmenopausal women with osteoporosis, alendronate produced significantly greater increases in bone mineral density (BMD) in the spine and hip"
-
Hot Flushes Associated With Raloxifene Not as Much a Problem as Clinical Data Suggest - Doctor's Guide, 10/3/03
-
Consistent Effect of Raloxifene on Reduction of Vertebral Fracture Risk in Postmenopausal Women - Doctor's Guide, 9/25/03
-
Researchers Study Effects of Raloxifene on Markers of Cardiovascular Risk in Non-Caucasian Postmenopausal Women with Osteoporosis - Doctor's Guide, 9/25/03
- Raloxifene Safe, Effective in Postmenopausal Women - Medscape, 7/23/03
-
Raloxifene Increases Bone Mineral Density and Decreases Osteoporosis Incidence Over 5 Years - Doctor's Guide, 7/21/03 -
"Compared with placebo,
raloxifene treatment significantly reduced values of bone turnover markers, including osteocalcin, bone-specific alkaline phosphatase,
and urinary C-telopeptide. In addition, raloxifene treatment was associated with 2.8% increase in BMD in the lumbar spine (P<0.001) and a 2.6% increase in total hip BMD ... Incidence of hot flashes was
higher among women taking raloxifene"
- Evista Strengthens Bones, Safe on Uterus - WebMD, 7/18/03
- Osteoporosis Drug [Evista] a Better HRT? - WebMD, 6/5/03
- Once-Weekly Alendronate Superior to Raloxifene for Spine and Hip BMD - Medscape, 4/28/03
-
Raloxifene May Be Useful In Postmenopausal Primary Hyperparathyroidism - Doctor's Guide, 3/28/03
- What’s Best for Bones? - Dr. Weil, 3/4/03
-
Raloxifene Improves Postmenopausal Endothelial Function - Doctor's Guide, 3/4/03
-
Endothelium-Dependent/Independent Vasodilatation Not Influenced By Raloxifene - Doctor's Guide, 2/26/03
-
Postmenopausal Vaginal Atrophy Creams Work With Raloxifene - Doctor's Guide, 2/19/03
-
Evista: Major Cardiovascular Benefits? - Physician's Weekly, 2/3/03 -
"Evista, a drug widely used to treat osteoporosis, was
associated with a 62% reduction in the risk of all strokes in postmenopausal women at high risk for heart disease"
-
Raloxifene/Sodium Fluoride Produces Significant Bone Mineral Density Increase In Postmenopausal Osteoporosis - Doctor's Guide, 1/24/03
-
Raloxifene Decreases Fracture Severity in Postmenopausal Women with Osteoporosis - Doctor's Guide, 12/31/02
- Raloxifene Halves Cerebrovascular Risk in Postmenopausal Women - Medscape, 11/20/02 -
"raloxifene (Evista) reduces the risk of stroke or transient
ischemic attack (TIA) in postmenopausal women by 48% over four years"
-
Long-Term Raloxifene Effects Evaluated In Postmenopausal Women - Doctor's Guide, 10/23/02
-
Raloxifene Continues to Prevent Vertebral Fractures at Four Years - Doctor's Guide, 10/7/02
-
Women Less Likely to Discontinue Raloxifene than Estrogen-Progestin Therapy - Doctor's Guide, 10/7/02
-
Direct Switch from Low-dose Estrogen to Raloxifene Supported - Doctor's Guide, 10/7/02
- Raloxifene Safely Reduces Vertebral Fractures After Menopause - Medscape, 10/7/02
-
Treating & Preventing Osteoporosis - Life Extension Magazine, 9/02 -
"From systematic research the best external evidence is available for a supplementation with calcium and vitamin D and a therapy with the
bisphosphonates alendronate or risedronate, as well as the selective estrogen receptor modulator raloxifene (Evista)."
- Osteoporosis Drug May Protect Brain - WebMD, 7/24/02 -
"when elderly women were given Evista at twice the approved osteoporosis dose, their risk for
developing a pre-Alzheimer's condition was cut by 33% compared with women taking a placebo"
-
High-Dose Raloxifene Associated with Reduced Risk for Cognitive Impairment - Doctor's Guide, 7/22/02
- Task Force Considers Tamoxifen, Raloxifene to Prevent Breast Cancer - Medscape, 7/2/02
- Drugs [tamoxifen and Evista] Prevent Breast Cancer -- for Some - WebMD, 7/1/02
-
One-Year Raloxifene Reduces Vertebral Fracture Risk In Osteoporotic Women - Doctor's Guide, 5/28/02
-
Raloxifene Has No Effect Over Time On Postmenopausal Cardiac Function - Doctor's Guide, 5/7/02
-
Study: Drug May Lower Heart Risks - Intelihealth, 2/20/02
- Designer Estrogen Compares to Real Thing - WebMD, 2/19/02
-
Raloxifene, Estrogen Act Similarly On Postmenopausal Bone Tissue - Doctor's Guide, 2/19/02
-
Insulin Sensitivity, Glycemic Control Unaffected By Raloxifene In Postmenopausal Diabetics - Doctor's Guide, 1/29/02
- Tamoxifen, Raloxifene Show Preclinical Cross-resistance - Doctor's Guide, 12/12/01
- Raloxifene May Add Antidepressant Efficacy to Selective Serotonin Reuptake Inhibitor Therapy for Depression - Doctor's Guide, 11/20/01
- Tamoxifen, Raloxifene Prove Effective In Pre-Pubertal Gynecomastia - Doctor's Guide, 7/12/01
- Raloxifene May Be Contraindicated in Some Ovarian Cancers - Doctor's Guide, 7/3/01
- Raloxifene Use Safe In Postmenopausal Women With Type 2 Diabetes - Doctor's Guide, 6/25/01
-
Study Rates Estrogen Alternative [Evista/raloxifene] - Intelihealth, 4/19/01 -
"mimics estrogen in strengthening bones but without the increased risk of breast cancer ... did not have an
overall effect on cognitive function ... Results of estrogen studies have been mixed, but taken together they suggest the hormone reduces the risk of Alzheimer's disease by about 30 percent"
-
No Cardiovascular Harm With Osteoporosis Drug, Raloxifene - Doctor's Guide, 3/21/01
- Risk Of Symptomatic Spinal Fractures Reduced With Evista (Raloxifene HCl) - Doctor's Guide, 10/31/00
- FDA Approves Evista For Postmenopausal Osteoporosis - Doctor's Guide, 10/1/99
- Raloxifene Effective In Postmenopausal Women With Osteoporosis - Doctor's Guide, 8/17/99
- Drug That Treats Osteoporosis Also Decreases Risk Of Breast Cancer - Doctor's Guide, 6/15/99
- FDA Grants Priority Review To Evista For Osteoporosis - Doctor's Guide, 6/4/99
- Evista Reduces Breast Cancer Incidence In Postmenopausal Women - Doctor's Guide, 12/11/98
- FDA Approves CombiPatch Hormone Replacement Therapy - Doctor's Guide, 8/10/98
- FDA Approves Estratab For Osteoporosis Prevention - Doctor's Guide, 3/11/98
- Raloxifene Shows Promise As Ideal Hormone Therapy For Some Women - Doctor's Guide, 1/28/98
- Evista Prevents Osteoporosis In Postmenopausal Women - Doctor's Guide, 12/10/97
Abstracts:
Related Searches:
70629
|
